Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Dosisundersøgelse af ORKA-001 hos patienter med moderat til svær plaque psoriasis (EVERLAST-B)

3. november 2026 opdateret af: Oruka Therapeutics, Inc.

Et multicenter, randomiseret, dobbeltblindet, placebokontrolleret, dosisinterval-bestemmelsesstudie med ORKA-001 hos deltagere med moderat til svær plaque-psoriasis

This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This is a multicenter, randomized, double-blinded, placebo-controlled, dose ranging study designed to identify the optimal induction dosing regimen of ORKA-001 in approximately 160 adult participants with moderate-to-severe plaque psoriasis.

The study will evaluate the efficacy and safety of 3 induction dosing regimens of ORKA-001 compared to placebo and will include 3 maintenance regimens.

The study will consist of 4 periods:

  • Screening Period of up to 6 weeks
  • Induction Period of up to 28 weeks (Day 1 [Baseline] to Week 28)
  • Maintenance Period of up to approximately 72 weeks (Week 28 to Week 100)
  • Post-treatment Follow-up Period: Participants will have the option to enter the open-label extension (OLE) study. Participants who opt out of the OLE study and/or withdraw from the study must be followed for 48 weeks after the End of Treatment (EOT)/Early Termination (ET) visit.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

160

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • British Columbia
      • Surrey, British Columbia, Canada, V3R 6A7
        • Oruka Therapeutics Investigative Site
      • Surrey, British Columbia, Canada, V3V 0C6
        • Oruka Therapeutics Investigative Site
    • New Brunswick
      • Fredericton, New Brunswick, Canada, E3B 1G9
        • Oruka Therapeutics Investigative Site
    • Ontario
      • Ajax, Ontario, Canada, L1S 7K8
        • Oruka Therapeutics Investigative Site
      • Markham, Ontario, Canada, L3P 1X3
        • Oruka Therapeutics Investigative Site
      • Peterborough, Ontario, Canada, K9J 5K2
        • Oruka Therapeutics Investigative Site
    • Quebec
      • Montreal, Quebec, Canada, HZX 2V1
        • Oruka Therapeutics Investigative Site
      • Québec, Quebec, Canada, G1V 4X7
        • Oruka Therapeutics Investigative Site
    • Arizona
      • Phoenix, Arizona, Forenede Stater, 85032
        • Oruka Therapeutics Investigative Site
    • Arkansas
      • North Little Rock, Arkansas, Forenede Stater, 72117
        • Oruka Therapeutics Investigative Site
    • California
      • Los Angeles, California, Forenede Stater, 90045
        • Oruka Therapeutics Investigative Site
      • Los Angeles, California, Forenede Stater, 90024
        • Oruka Therapeutics Investigative Site
      • San Diego, California, Forenede Stater, 92123
        • Oruka Therapeutics Investigative Site
    • Florida
      • Miami, Florida, Forenede Stater, 33126
        • Oruka Therapeutics Investigative Site
    • Illinois
      • Rolling Meadows, Illinois, Forenede Stater, 60008
        • Oruka Therapeutics Investigative Site
    • Indiana
      • Plainfield, Indiana, Forenede Stater, 46168
        • Oruka Therapeutics Investigative Site
    • Maryland
      • Rockville, Maryland, Forenede Stater, 20850
        • Oruka Therapeutics Investigative Site
    • New York
      • Kew Gardens, New York, Forenede Stater, 11415
        • Oruka Therapeutics Investigative Site
    • North Carolina
      • Chapel Hill, North Carolina, Forenede Stater, 27516
        • Oruka Therapeutics Investigative Site
    • Ohio
      • Cleveland, Ohio, Forenede Stater, 44106
        • Oruka Therapeutics Investigative Site
      • Mason, Ohio, Forenede Stater, 45040
        • Oruka Therapeutics Investigative Site
    • Oregon
      • Portland, Oregon, Forenede Stater, 97201
        • Oruka Therapeutics Investigative Site
      • Portland, Oregon, Forenede Stater, 97210
        • Oruka Therapeutics Investigative Site
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forenede Stater, 19104
        • Oruka Therapeutics Investigative Site
    • Texas
      • Frisco, Texas, Forenede Stater, 75033
        • Oruka Therapeutics Investigative Site
      • Houston, Texas, Forenede Stater, 77004
        • Oruka Therapeutics Investigative Site
      • Webster, Texas, Forenede Stater, 77598
        • Oruka Therapeutics Investigative Site
    • Virginia
      • Norfolk, Virginia, Forenede Stater, 23502
        • Oruka Therapeutics Investigative Site
    • Barcelona
      • Badalona, Barcelona, Spanien, 08916
        • Oruka Therapeutics Investigative Site
      • Barcelona, Barcelona, Spanien, 08041
        • Oruka Therapeutics Investigative Site
    • Madrid
      • Madrid, Madrid, Spanien, 28002
        • Oruka Therapeutics Investigative Site
      • Madrid, Madrid, Spanien, 28046
        • Oruka Therapeutics Investigative Site
    • Baden-Wuerrtemberg
      • Heidelberg, Baden-Wuerrtemberg, Tyskland, 69120
        • Oruka Therapeutics Investigative Site
    • Hesse
      • Frankfurt am Main, Hesse, Tyskland, 60590
        • Oruka Therapeutics Investigative Site
    • Lower Saxony
      • Bad Bentheim, Lower Saxony, Tyskland, 48455
        • Oruka Therapeutics Investigative Site
    • Schleswig-Holstein
      • Kiel, Schleswig-Holstein, Tyskland, 24105
        • Oruka Therapeutics Investigative Site

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Participants ≥ 18 years of age

  2. Have a diagnosis of plaque psoriasis for > 6 months

  3. Have moderate-to-severe chronic plaque psoriasis defined as:

    1. BSA ≥ 10%, and
    2. PASI ≥ 12, and
    3. IGA score of ≥ 3 on a 5-point scale
  4. Candidate for systemic therapy or phototherapy

  5. Women of childbearing potential must have a negative pregnancy test.

Exclusion Criteria:

  1. Nonplaque forms of psoriasis (including guttate, erythrodermic, or pustular) or drug-induced psoriasis
  2. Significant history or clinical manifestation of any metabolic, other dermatological, hepatic, renal, hematologic, pulmonary, cardiovascular, gastrointestinal, neurologic, respiratory, endocrine, or psychiatric disorder, or any infectious disease
  3. History of malignancy, except for non-melanoma skin cancer or cancer curatively treated ≥ 5 years, without evidence of recurrence
  4. A known hypersensitivity to any components of the ORKA-001 drug product
  5. Women who are breastfeeding or plan to breastfeed during the study

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: (Induction Period - Arm 1) ORKA-001

Participants will receive 37.5 mg ORKA-001 per protocol Induction regimen.

ORKA-001 administered by subcutaneous (SC) injection

Eksperimentel: (Induction Period - Arm 2) ORKA-001

Participants will receive 300 mg ORKA-001 per protocol Induction regimen.

ORKA-001 administered by subcutaneous (SC) injection

Eksperimentel: (Induction Period - Arm 3) ORKA-001

Participants will receive 600 mg ORKA-001 per protocol Induction regimen.

ORKA-001 administered by subcutaneous (SC) injection

Placebo komparator: (Induction Period - Arm 4) Placebo

Participants will receive Placebo per protocol Induction regimen.

Placebo administered by subcutaneous (SC) injection

Eksperimentel: (Maintenance Period - Arm 1) ORKA-001

Participants will receive 300 mg ORKA-001 per protocol Maintenance regimen, based on protocol defined response.

ORKA-001 administered by subcutaneous (SC) injection

Eksperimentel: (Maintenance Period - Arm 2) ORKA-001

Participants will receive 600 mg ORKA-001 per protocol Maintenance regimen, based on protocol defined response.

ORKA-001 administered by subcutaneous (SC) injection

Placebo komparator: (Maintenance Period - Arm 3) Placebo

Participants will receive Placebo per protocol Maintenance regimen, based on protocol defined response.

Placebo administered by subcutaneous (SC) injection

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Proportion of Participants Achieving 100% Reduction in PASI Score at Week 16
Tidsramme: Week 16

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Week 16

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Proportion of Participants Who Achieve an IGA = 0 (Clear) at Week 16
Tidsramme: Week 16

The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

Week 16
Proportion of Participants Achieving 90% Reduction in PASI Score at Week 16
Tidsramme: Week 16

Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Week 16
Proportion of Participants Who Achieve an IGA = 0 (Clear) or 1 (Almost Clear) at Week 16
Tidsramme: Week 16

The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

Week 16
Proportion of Participants Maintaining 100% Reduction in PASI Score at Week 100
Tidsramme: Week 100

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Week 100
Proportion of Participants Maintaining an IGA = 0 (Clear) at Week 100
Tidsramme: Week 100

The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

Week 100
Proportion of Participants Maintaining 90% Reduction in PASI Score at Week 100
Tidsramme: Week 100

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Week 100
Proportion of Participants Maintaining an IGA = 0 (Clear) or 1 (Almost Clear) at Week 100
Tidsramme: Week 100

The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

Week 100
Proportion of Participants Maintaining 75% Reduction in PASI Score at Week 100
Tidsramme: Week 100

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Week 100
Incidence of Treatment-emergent Adverse Events (TEAEs) and TEAEs of Special Interest (TEAESIs)
Tidsramme: Day 1 through Week 100

Incidence of treatment adverse events, treatment adverse events of special interest, and clinically significant changes from baseline in vital signs, clinical laboratory parameters and electrocardiograms

Day 1 through Week 100

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

3. december 2025

Primær færdiggørelse (Faktiske)

21. oktober 2026

Studieafslutning (Anslået)

1. december 2028

Datoer for studieregistrering

Først indsendt

16. december 2025

Først indsendt, der opfyldte QC-kriterier

16. december 2025

Først opslået (Faktiske)

18. december 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

6. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

3. november 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • ORKA-001-114

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .